Visceral leishmaniasis (VL) is one of the major infectious diseases affecting the poorest regions of the world. Current therapy is not very much satisfactory. The alarming rise of drug resistance and the unavailability of an effective vaccine against VL urges research towards identifying new targets or biomarkers for its effective treatment. New technology developments offer some fresh hope in its diagnosis, treatment, and control. DNA microarray approach is now broadly used in parasitology research to facilitate the thoughtful of mechanisms of disease and identification of drug targets and biomarkers for diagnostic and therapeutic development. An electronic search on "VL" and "Microarray" was conducted in Medline and Scopus and papers published in the English mentioning use of DNA microarray on VL were selected and read to write this paper review. Functional analysis and interpretation of microarray results remain very challenging due to the inherent nature of experimental workflows, access, cost, and complexity of data obtained. We have explained and emphasized the use of curate knowledge of microarray in the case of VL for the identification of therapeutic target and biomarker and their selection/implementation in clinical use.

中文翻译：

---

内脏利什曼病基于 DNA 的微阵列研究：鉴定用于诊断、预后和治疗药物靶标的生物标志物。


内脏利什曼病（VL）是影响世界最贫困地区的主要传染病之一。目前的治疗效果不是很令人满意。耐药性的惊人上升和有效疫苗的缺乏促使人们进行研究以确定新的靶点或生物标志物以进行有效的治疗。新技术的发展为其诊断、治疗和控制带来了新的希望。 DNA 微阵列方法现已广泛应用于寄生虫学研究，以促进对疾病机制的思考以及药物靶点和生物标志物的识别，以促进诊断和治疗的发展。在 Medline 和 Scopus 上对“VL”和“Microarray”进行了电子检索，并选择并阅读了以英文发表的提及在 VL 上使用 DNA 微阵列的论文，以撰写本文评论。由于实验工作流程、获取数据的访问、成本和复杂性的固有性质，微阵列结果的功能分析和解释仍然非常具有挑战性。我们已经解释并强调了在 VL 案例中使用微阵列的丰富知识来识别治疗靶点和生物标志物及其在临床使用中的选择/实施。